The company has always regarded scientific research and development as the supporting force for the sustainable development of the enterprise, and is one of the pharmaceutical enterprises with more scientific research investment in China. The company takes the Lianyungang R&D Center as the carrier of scientific research, and its independent innovation capability is constantly improving. The company has been rated as a national high-tech enterprise, a Jiangsu Province "Specialized, Refined, Special, and Innovative" SME, a second-class safety production standardization enterprise in Jiangsu Province, a three-star cloud enterprise in Jiangsu Province and an informatization-industrialization integration demonstration and pilot enterprise in Jiangsu Province; it has built a number of R&D platforms, such as the Jiangsu Province Engineering Technology Research Center, the Jiangsu Province Enterprise Graduate Workstation and the Lianyungang City Enterprise Technology Center; it has undertaken a number of scientific and technological plan projects, applied for more than 30 kinds of intellectual property rights, and has 13 valid authorized invention patents and 3 registered trademarks. The acquisition of these honors and achievements indicates that the quality and management level of the enterprise's drug production are in the forefront of the national pharmaceutical industry.

Yutian Pharmaceutical has built production bases in Lianyungang, Jiangsu and Jiamusi, Heilongjiang, mainly products have obtained the two-in-one certification of GMP and registration site inspection; the company's multiple products have completed the overseas registration declaration in the United States, the European Union and India, among which the Ivabradine hydrochloride, and ribociclib passed the inspection of the US FDA with zero defects, iodixanol has obtained the EU CEP certification. The company always takes customer demand as the guide, relies on excellent R&D innovation ability and strong production and manufacturing capability, uses purification workshops, synthesis workshops that have passed GMP standards, and invests a batch of modern high-tech production equipment, from high-pressure 12MPA reaction to atmospheric reaction, from deep-cold -100° reaction to high-temperature +250° reaction, from gram-level to ton-level reaction of various harsh conditions reaction equipment and modern standard laboratories and advanced quality control centers, to produce high-quality APIs and intermediates for major pharmaceutical enterprises.

Looking ahead, the company is committed to maintaining its leadership in the field of APIs and intermediates while delivering high-quality products to our customers. Guided by the principles of 'safety, environmental protection, innovation, efficiency, and quality,' we are driving a strategic transformation: shifting from API intermediates to finished pharmaceuticals, expanding from chemical drugs to a combination of chemical and biological drugs, evolving from imitation-based R&D to innovation-led development, and balancing domestic focus with coordinated global growth. Our goal is to steadily build an innovative, international pharmaceutical enterprise.

Heilongjiang Dino Pharmaceutical Co., Ltd.

Heilongjiang Dino Pharmaceutical Co., Ltd. was established in 2021 and is headquartered in the Chemical Park of the Economic Development Zone in Huanan County, Jiamusi City. As the core production base of Yutian Pharmaceutical, its main products encompass four major categories: contrast agents, anesthetics, cardiovascular drugs, and antibacterial and anti-inflammatory agents.

The company has established a mature pilot platform for biopharmaceutical intermediates and APIs in Heilongjiang Province. Recognized for its technological innovation, the company has received multiple accolades from the city of Jiamusi, including 'Enterprise with Special Contribution to Industrial Economic Growth,' 'Leading Technology Demonstration Enterprise,' and 'Outstanding Private Enterprise in Employment Generation.' Additionally, five of its products have been designated as Key New Products by the Provincial Department of Industry and Information Technology. The company has applied for over 10 domestic patents and currently holds 8 granted patents.